Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

efmarodocokin alfa

A recombinant fusion protein consisting of human cytokine interleukin (IL) 22 (IL-22) fused to the Fc portion of human immunoglobulin (Ig) G4, with potential cell protective and immunomodulatory activities. Upon administration of efmarodocokin alfa, IL-22 binds to its cognate receptor IL-22R, which is highly expressed in parenchymal tissues and epithelial cells at mucosal surfaces. This leads to the activation of IL-22/IL-22R-mediated signal transduction pathways, and results in the activation of signal transducer and activator of transcription 3 (STAT3). STAT3 activation may have a protective and regenerative effect and may protect against the development of various inflammatory and immunological diseases. IL-22, a member of the IL-10 family of cytokines, is produced by various immune cells and upregulated during inflammation. It plays a key role in controlling immune responses and bacterial infection, and in the enhancement of intestinal barrier function, gut immunity, and tissue repair.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:IL-22Fc
recombinant human interleukin-22 IgG4-Fc fusion protein UTTR1147A
Code name:RG 7880
RG-7880
RO7021610
UTTR1147A
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search